Positive new data suggests that more people facing advanced breast cancer may be able to put off treatment with harsh ...

For the first time, a medicine aimed directly at the HER2 protein improved overall survival after gastric cancer progressed ...

The DESTINY-Breast09 study, reported at ASCO, compared antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan) and ...

Explore how cutting-edge agents like alpelisib, capivasertib, MEK and ERK inhibitors, and JAK inhibitors are reshaping the ...

AI-assisted training notably improved pathologist accuracy in HER2-low breast cancer, reducing misclassification and ...

Among the 43 evaluable patients treated with sevabertinib, the confirmed objective response rate was 72.1%.

In an interim analysis from the DESTINY-Breast09 study, the combination of the antibody-drug conjugate trastuzumab deruxtecan ...

The FDA has accepted and granted priority review to an NDA for sevabertinib in previously treated HER2+ non-small cell lung ...

Treating breast cancer patients with AstraZeneca's experimental pill camizestrant at the first sign of resistance to standard ...

This priority review designation for sevabertinib in previously treated HER2-mutant non–small cell lung cancer is supported ...